PREX2

Across TCGA pan-cancer cohorts, PREX2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of PREX2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where PREX2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PREX2 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC, LUAD, and CCRCC are the cancer types where PREX2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PREX2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	II,III,IV	−1.687	<.001	9	view →
LUAD	Female	II,III,IV	−1.014	<.001	9	view →
CCRCC	All	All	+0.423	<.001	7	view →
PDAC	Female	III,IV	+2.125	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

PREX2–LSCC

Open the LSCC breakdown →